Simultaneous SiRNA-mediated Knockdown of Antiapoptotic BCL2, Bcl-xL, XIAP and Survivin in Bladder Cancer Cells

Overview

Journal Int J Oncol

Specialty Oncology

Date 2012 Jul 17

PMID 22797576

Citations 13

Authors

Doreen Kunze

Kai Kraemer

Kati Erdmann

Michael Froehner

Manfred P Wirth

Susanne Fuessel

Affiliations

Soon will be listed here.

Abstract

Bladder cancer (BCa) represents the ninth most common malignancy worldwide. Despite intensive treatment with surgery and chemotherapy the prognosis for BCa patients particularly at advanced stages is poor. The ability to evade apoptosis is a hallmark of cancer cells. Since the antiapoptotic genes BCL2, Bcl-xL, XIAP and survivin are frequently upregulated in BCa tissues, their combined siRNA-mediated knockdown might be more potent in decreasing BCa growth than the single inhibition of one target. Against each target two siRNAs were selected that specifically reduced the mRNA and protein levels of their appropriate target in EJ28 and J82 BCa cells. Inhibition of survivin provoked the strongest antiproliferative effect of all single target treatments, for example cell counts decreased by 50%. Simultaneous targeting of all four antiapoptotic genes downregulated expression levels of all targets and mediated significant reductions in cell viability and cell counts as well as induction of apoptosis. In EJ28 cells, combined knockdown of BCL2, Bcl-xL, XIAP and survivin caused a 2.5-fold enhancement in apoptosis rate and reduced cellular viability by 40%. Therefore, simultaneous knockdown of antiapoptotic BCL2, Bcl‑xL, XIAP and survivin may represent a promising treatment option for bladder cancer.

Citing Articles

PolyPurine Reverse Hoogsteen Hairpins Work as RNA Species for Gene Silencing.

Aubets E, Chillon M, Ciudad C, Noe V Int J Mol Sci. 2021; 22(18).

PMID: 34576188 PMC: 8466063. DOI: 10.3390/ijms221810025.

Silver Nanoparticles Surface-Modified with Carbosilane Dendrons as Carriers of Anticancer siRNA.

Pedziwiatr-Werbicka E, Gorzkiewicz M, Horodecka K, Abashkin V, Klajnert-Maculewicz B, Pena-Gonzalez C Int J Mol Sci. 2020; 21(13).

PMID: 32629868 PMC: 7370058. DOI: 10.3390/ijms21134647.

Mechanism of inhibition of Shiga-toxigenic SubAB cytotoxicity by steroids and diacylglycerol analogues.

Yahiro K, Nagasawa S, Ichimura K, Takeuchi H, Ogura K, Tsutsuki H Cell Death Discov. 2018; 4:22.

PMID: 29531819 PMC: 5841432. DOI: 10.1038/s41420-017-0007-4.

Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?.

Wezel F, Vallo S, Roghmann F Transl Androl Urol. 2018; 6(6):1067-1080.

PMID: 29354494 PMC: 5760384. DOI: 10.21037/tau.2017.09.18.

Synthesizing artificial devices that redirect cellular information at will.

Liu Y, Li J, Chen Z, Huang W, Cai Z Elife. 2018; 7.

PMID: 29319503 PMC: 5788502. DOI: 10.7554/eLife.31936.

References

Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, Takei Y . Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer. 2009; 125(12):2978-90. DOI: 10.1002/ijc.24382. View

Takizawa B, Uchio E, Cohen J, Wheeler M, Weiss R . Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. Cancer Invest. 2007; 25(8):678-84. DOI: 10.1080/07357900701600954. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Kunze D, Wuttig D, Fuessel S, Kraemer K, Kotzsch M, Meye A . Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res. 2008; 28(4B):2259-63. View

Sensintaffar J, Scott F, Peach R, Hager J . XIAP is not required for human tumor cell survival in the absence of an exogenous death signal. BMC Cancer. 2010; 10:11. PMC: 2827368. DOI: 10.1186/1471-2407-10-11. View

Glick S, HOWELL L, White R . Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol. 1996; 155(5):1754-7. View

Shangary S, Johnson D . Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia. 2003; 17(8):1470-81. DOI: 10.1038/sj.leu.2403029. View

Anderson E, Miller P, Ilsley D, Marshall W, Khvorova A, Stein C . Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Cancer Gene Ther. 2005; 13(4):406-14. DOI: 10.1038/sj.cgt.7700901. View

Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M . Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer. 2005; 116(1):100-4. DOI: 10.1002/ijc.21000. View

10.

Dohi T, Okada K, Xia F, Wilford C, Samuel T, Welsh K . An IAP-IAP complex inhibits apoptosis. J Biol Chem. 2004; 279(33):34087-90. DOI: 10.1074/jbc.C400236200. View

11.

Jeyaprakash A, Klein U, Lindner D, Ebert J, Nigg E, Conti E . Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell. 2007; 131(2):271-85. DOI: 10.1016/j.cell.2007.07.045. View

12.

Pollack A, Wu C, Czerniak B, Zagars G, Benedict W, McDonnell T . Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res. 1998; 3(10):1823-9. View

13.

Ploeg M, Aben K, Kiemeney L . The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27(3):289-93. PMC: 2694323. DOI: 10.1007/s00345-009-0383-3. View

14.

Velculescu V, Madden S, Zhang L, Lash A, Yu J, Rago C . Analysis of human transcriptomes. Nat Genet. 1999; 23(4):387-8. DOI: 10.1038/70487. View

15.

Ferlay J, Parkin D, Steliarova-Foucher E . Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46(4):765-81. DOI: 10.1016/j.ejca.2009.12.014. View

16.

Ruckert F, Samm N, Lehner A, Saeger H, Grutzmann R, Pilarsky C . Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis. BMC Cancer. 2010; 10:379. PMC: 2912871. DOI: 10.1186/1471-2407-10-379. View

17.

Herr H, Dotan Z, Donat S, Bajorin D . Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007; 177(2):437-43. DOI: 10.1016/j.juro.2006.09.027. View

18.

Tan M, Ooi J, Ismail N, Moad A, Tengku Muhammad T . Programmed cell death pathways and current antitumor targets. Pharm Res. 2009; 26(7):1547-60. DOI: 10.1007/s11095-009-9895-1. View

19.

Yang D, Song X, Zhang J, Ye L, Wang S, Che X . Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells. Acta Biochim Biophys Sin (Shanghai). 2010; 42(2):137-44. DOI: 10.1093/abbs/gmp118. View

20.

Ong F, Moonen L, Gallee M, ten Bosch C, Zerp S, Hart A . Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol. 2001; 61(2):169-75. DOI: 10.1016/s0167-8140(01)00421-2. View